<DOC>
	<DOCNO>NCT03038880</DOCNO>
	<brief_summary>This Phase II , multicenter , randomize , active comparator-controlled , 52-week study investigate efficacy , safety pharmacokinetics RO6867461 ( RG7716 ) administer extended dosing regimens treatment-naive participant nAMD . Only one eye chosen study eye .</brief_summary>
	<brief_title>Study Evaluate RO6867461 ( RG7716 ) Extended Durability Treatment Neovascular Age Related Macular Degeneration ( nAMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Inclusion Criteria Treatmentnaive CNV secondary AMD Subfoveal juxtafoveal CNV subfoveal component related CNV activity Active CNV BCVA letter score 73 24 letter ( inclusive ) CNV due cause AMD Retinal pigment epithelial tear involve macula On fundus fluorescein angiography ( FFA ) subretinal hemorrhage , fibrosis atrophy &gt; 50 % total lesion area and/or involve fovea Cataract surgery within 3 month baseline assessment Uncontrolled blood pressure</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>